Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 32% Improvement Relative Risk Danjuma et al. Colchicine for COVID-19 META ANALYSIS Favors colchicine Favors control
Does Colchicine Reduce Mortality in Patients with Covid-19 Clinical Syndrome? An Umbrella Review of Published Meta-Analyses
Danjuma et al., Elsevier BV, doi:10.2139/ssrn.4447127 (Preprint), PROSPERO CRD42023397246
Danjuma et al., Does Colchicine Reduce Mortality in Patients with Covid-19 Clinical Syndrome? An Umbrella Review of Published.., Elsevier BV, doi:10.2139/ssrn.4447127 (Preprint), PROSPERO CRD42023397246
May 2023   Source   PDF  
  All Studies   Meta
Umbrella review of 18 colchicine meta analyses, showing significantly lower COVID-19 mortality with colchicine.
Currently there are 48 colchicine studies and meta analysis shows:
Mortality33% lower [21‑43%]
Ventilation29% lower [-15‑56%]
ICU admission25% lower [3‑43%]
Hospitalization17% lower [8‑25%]
Cases9% more [-6‑27%]
risk of death, 32.0% lower, OR 0.68, p < 0.001, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Danjuma et al., 17 May 2023, preprint, 7 authors, trial PROSPERO CRD42023397246.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: review of published meta-analyses iew ed Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? an umbrella Mohammed I Danjuma 1,2,3, Rana Sayed4, Maryam Aboughalia4, Aseel Hassona4, Basant Selim Elsayed4, Mohamed Elshafei5, Abdelnaser Elzouki1,2,4 1. Department of Internal Medicine, Hamad Medical Corporation, Doha Qatar ev 2. Department of Internal Medicine, Weill Cornell College of Medicine, New York, and Doha Qatar 3. NHS Grampian (Dr Grays Hospital) er r 4. Department of Internal Medicine, Qatar University College of Medicine rin tn ot pe 5. Department of Pharmacy, Hamad Medical Corporation, Doha Qatar Corresponding author: Dr. Mohammed Ibn-Mas’ud Danjuma ep Consultant Physician and Clinical Pharmacologist Department of Internal Medicine, Weill Cornell College of Medicine New York and Doha Qatar Pr Email:; 1 This preprint research paper has not been peer reviewed. Electronic copy available at: iew ed Abstract Background Despite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Covid-19 clinical syndrome. ev Methods: In this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of er r Abstracts of Reviews of Effectiveness between 1st January 2020 and 31st January 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with Covid-19. This was to ascertain the exact relationship between colchicine pe exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews. ot Results: We included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. tn Colchicine exposure was associated with an overall reduction of about 35% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58-0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected rin for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%). ep Conclusion: In a pooled umbrella evaluation of published meta-analyses of Covid-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains Pr uncertain if this effect could potentially be attenuated or augmented by Covid-19 vaccination. PROSPERO Registration number: CRD42023397246. 2 This preprint research paper has not been peer reviewed. Electronic copy available at: iew ed Key words: COVID-19; Colchicine; Meta-analysis; Mortality; Umbrella Background Successful immunization with a variety of approved Coronavirus Disease 2019 (COVID-19) vaccines has significantly contributed to containing both the spread and the adverse consequences of this nascent infection. However, the exact role of clinical therapeutics in its management is still evolving. Since the onset of the COVID-19 pandemic, repurposing of drugs ev with..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop